# Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Source: https://onco.cc/trials/nct05000294/  
OnCo record `nct05000294` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of atezolizumab and tivozanib in gallbladder cancer, run by University of Florida, now recruiting.

## Summary

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types is a phase 1/2 interventional study registered as NCT05000294 by University of Florida, with a registry enrolment figure of 29 participants, started 2021-12-07 and due to reach its primary completion in 2026-12. Interventions recorded: Atezolizumab, Tivozanib. Conditions listed: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer. Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT05000294
- Phase: 1/2
- Setting: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
- Sponsor: University of Florida
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT05000294: https://clinicaltrials.gov/study/NCT05000294

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Tivozanib](https://onco.cc/drugs/tivozanib/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct05000294.json